Reply: Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes

Allie S. Carew; Andrew P. Levy; Henry N. Ginsberg; Eric B. Rimm; Leah E. Cahill

doi:10.1016/j.jacc.2020.04.035

Reply: Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes

Allie S. Carew, Andrew P. Levy, Henry N. Ginsberg, Eric B. Rimm, Leah E. Cahill

Medicine

Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2996-2997
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	75
Issue number	23
DOIs	https://doi.org/10.1016/j.jacc.2020.04.035
Publication status	Published - Jun 16 2020

Bibliographical note

Funding Information:
Please note: This study was funded by a Dalhousie University Department of Medicine Ad Hoc Operating Grant and a Nova Scotia Health Authority Research Fund grant to Dr. Cahill. Additional funding was received in part from the Israel Science Foundation (grant 190/16) to Dr. Levy. The original ACCORD study was funded by the U.S. National Institutes of Health. The funding sources were not involved in data collection, data analysis, or manuscript drafting. Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Associate Editor and Guest Editor-in-Chief for this paper.

Funding Information:
Please note: This study was funded by a Dalhousie University Department of Medicine Ad Hoc Operating Grant and a Nova Scotia Health Authority Research Fund grant to Dr. Cahill. Additional funding was received in part from the Israel Science Foundation (grant 190/16) to Dr. Levy. The original ACCORD study was funded by the U.S. National Institutes of Health. The funding sources were not involved in data collection, data analysis, or manuscript drafting. Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Associate Editor and Guest Editor-in-Chief for this paper.

ASJC Scopus Subject Areas

Cardiology and Cardiovascular Medicine

PubMed: MeSH publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

Access to Document

10.1016/j.jacc.2020.04.035

Cite this

@article{9343b6535b1541f5b6eda73a3cb9220a,

title = "Reply: Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes",

author = "Carew, {Allie S.} and Levy, {Andrew P.} and Ginsberg, {Henry N.} and Rimm, {Eric B.} and Cahill, {Leah E.}",

note = "Funding Information: Please note: This study was funded by a Dalhousie University Department of Medicine Ad Hoc Operating Grant and a Nova Scotia Health Authority Research Fund grant to Dr. Cahill. Additional funding was received in part from the Israel Science Foundation (grant 190/16) to Dr. Levy. The original ACCORD study was funded by the U.S. National Institutes of Health. The funding sources were not involved in data collection, data analysis, or manuscript drafting. Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Associate Editor and Guest Editor-in-Chief for this paper. Funding Information: Please note: This study was funded by a Dalhousie University Department of Medicine Ad Hoc Operating Grant and a Nova Scotia Health Authority Research Fund grant to Dr. Cahill. Additional funding was received in part from the Israel Science Foundation (grant 190/16) to Dr. Levy. The original ACCORD study was funded by the U.S. National Institutes of Health. The funding sources were not involved in data collection, data analysis, or manuscript drafting. Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Associate Editor and Guest Editor-in-Chief for this paper. ",

year = "2020",

month = jun,

day = "16",

doi = "10.1016/j.jacc.2020.04.035",

language = "English",

volume = "75",

pages = "2996--2997",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "23",

}

TY - JOUR

T1 - Reply

T2 - Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes

AU - Carew, Allie S.

AU - Levy, Andrew P.

AU - Ginsberg, Henry N.

AU - Rimm, Eric B.

AU - Cahill, Leah E.

N1 - Funding Information: Please note: This study was funded by a Dalhousie University Department of Medicine Ad Hoc Operating Grant and a Nova Scotia Health Authority Research Fund grant to Dr. Cahill. Additional funding was received in part from the Israel Science Foundation (grant 190/16) to Dr. Levy. The original ACCORD study was funded by the U.S. National Institutes of Health. The funding sources were not involved in data collection, data analysis, or manuscript drafting. Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Associate Editor and Guest Editor-in-Chief for this paper. Funding Information: Please note: This study was funded by a Dalhousie University Department of Medicine Ad Hoc Operating Grant and a Nova Scotia Health Authority Research Fund grant to Dr. Cahill. Additional funding was received in part from the Israel Science Foundation (grant 190/16) to Dr. Levy. The original ACCORD study was funded by the U.S. National Institutes of Health. The funding sources were not involved in data collection, data analysis, or manuscript drafting. Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Associate Editor and Guest Editor-in-Chief for this paper.

PY - 2020/6/16

Y1 - 2020/6/16

UR - http://www.scopus.com/inward/record.url?scp=85085689012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085689012&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2020.04.035

DO - 10.1016/j.jacc.2020.04.035

M3 - Letter

C2 - 32527410

AN - SCOPUS:85085689012

SN - 0735-1097

VL - 75

SP - 2996

EP - 2997

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 23

ER -

Reply: Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Cite this